We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 11. | 장 마감 후 (AMC) | $-0.28 | — | — | $84.18K | — | 예정 |
| FY2023 Q3 | 2022. 09. 30. | 시각 미정 | — | — | — | — | $7.13M | 보고됨 |
| FY2023 Q2 | 2022. 06. 30. | 시각 미정 | — | — | — | — | $5.42M |
Consensus PT $12.93 · 15 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 05. | Wedbush | — | 의견 유지 | Outperform → Outperform | — | Wedbush: Outperform |
| 2026. 04. 20. | Wedbush | — | 의견 유지 | Outperform → Outperform | — | Wedbush: Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2023 Q1 | 2022. 03. 31. | 시각 미정 | — | — | — | — | $2.91M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,003,474 | $4.18B | 0.00% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 1,198,644 | $3.3B | 0.01% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Stored first · Google News · Yahoo Finance (English)
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective Therapeutics Advances Next-Generation 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment Minichart
Perspective Therapeutics (NYSE: CATX) outlines 212Pb cancer pipeline update - Stock Titan
Perspective Therapeutics (NYSE: CATX) outlines 212Pb cancer pipeline update Stock Titan
Perspective Therapeutics, Inc. 8-K Filing Details for May 27, 2026: Company Information and SEC Compliance - Minichart
Perspective Therapeutics, Inc. 8-K Filing Details for May 27, 2026: Company Information and SEC Compliance Minichart
Shareholders of Perspective Therapeutics (NYSE: CATX) back board, auditor - Stock Titan
Shareholders of Perspective Therapeutics (NYSE: CATX) back board, auditor Stock Titan
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6 - 富途牛牛
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6 富途牛牛
Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX) - The Globe and Mail
Bank of America Securities Reaffirms Their Hold Rating on Perspective Therapeutics (CATX) The Globe and Mail